Table 9.

Overall survival, cancer-specific survival and prognosticators of them

Overall survival (OS)
Median OS	58.6 months (95% CI 28.2-NR)
1-Year OS	94% (95% CI 83–98%)
2-Year OS	82% (95% CI 67–91%)
3-Year OS	61% (95% CI 42–75%)
Cancer-specific survival (CSS)
Median CSS	Not reached
1-Year CSS	98% (95% CI 86–100%)
2-Year CSS	90% (95% CI 74–96%)
3-Year CSS	70% (95% CI 49–83%)
Prognosticators of shorter CSS
Pre-MWA CEA level > 10 ng/ml	p = 0.046*, HR = 3.53, 95% CI 1.02–12.2
≥ 3 Chemotherapy ± target therapy regimens	p = 0.019*, HR = 3.92, 95% CI 1.3–12.3
Prior lung resection	p = 0.1, HR = 0.27
Prior liver resection	p = 0.43, HR = 0.62
Lung as a first site of metastatic disease	p = 1, HR = 1

CEA carcinoembryonic antigen level, HR hazard ratio, CI confidence interval

^*Statistically significant values